Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2
Abstract The coronavirus disease 2019 (COVID‐19) pandemic has affected a large portion of the global population, both physically and mentally. Current evidence suggests that the rapidly evolving coronavirus subvariants risk rendering vaccines and antibodies ineffective due to their potential to evad...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-06-01
|
| Series: | MedComm |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/mco2.254 |
| _version_ | 1797802506723524608 |
|---|---|
| author | Yiying Xue Husheng Mei Yisa Chen James D. Griffin Qingsong Liu Ellen Weisberg Jing Yang |
| author_facet | Yiying Xue Husheng Mei Yisa Chen James D. Griffin Qingsong Liu Ellen Weisberg Jing Yang |
| author_sort | Yiying Xue |
| collection | DOAJ |
| description | Abstract The coronavirus disease 2019 (COVID‐19) pandemic has affected a large portion of the global population, both physically and mentally. Current evidence suggests that the rapidly evolving coronavirus subvariants risk rendering vaccines and antibodies ineffective due to their potential to evade existing immunity, with enhanced transmission activity and higher reinfection rates that could lead to new outbreaks across the globe. The goal of viral management is to disrupt the viral life cycle as well as to relieve severe symptoms such as lung damage, cytokine storm, and organ failure. In the fight against viruses, the combination of viral genome sequencing, elucidation of the structure of viral proteins, and identifying proteins that are highly conserved across multiple coronaviruses has revealed many potential molecular targets. In addition, the time‐ and cost‐effective repurposing of preexisting antiviral drugs or approved/clinical drugs for these targets offers considerable clinical advantages for COVID‐19 patients. This review provides a comprehensive overview of various identified pathogenic targets and pathways as well as corresponding repurposed approved/clinical drugs and their potential against COVID‐19. These findings provide new insight into the discovery of novel therapeutic strategies that could be applied to the control of disease symptoms emanating from evolving SARS‐CoV‐2 variants. |
| first_indexed | 2024-03-13T05:06:42Z |
| format | Article |
| id | doaj.art-47c42627687d44218496942800b31423 |
| institution | Directory Open Access Journal |
| issn | 2688-2663 |
| language | English |
| last_indexed | 2024-03-13T05:06:42Z |
| publishDate | 2023-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | MedComm |
| spelling | doaj.art-47c42627687d44218496942800b314232023-06-16T09:40:37ZengWileyMedComm2688-26632023-06-0143n/an/a10.1002/mco2.254Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2Yiying Xue0Husheng Mei1Yisa Chen2James D. Griffin3Qingsong Liu4Ellen Weisberg5Jing Yang6Department of Hematology, Tongji Hospital, Frontier Science Center for Stem Cell Research, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology Tongji University Shanghai ChinaAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science Chinese Academy of Sciences Hefei ChinaDepartment of Hematology, Tongji Hospital, Frontier Science Center for Stem Cell Research, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology Tongji University Shanghai ChinaDepartment of Medical Oncology, Dana‐Farber Cancer Institute Boston Massachusetts USAAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science Chinese Academy of Sciences Hefei ChinaDepartment of Medical Oncology, Dana‐Farber Cancer Institute Boston Massachusetts USADepartment of Hematology, Tongji Hospital, Frontier Science Center for Stem Cell Research, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology Tongji University Shanghai ChinaAbstract The coronavirus disease 2019 (COVID‐19) pandemic has affected a large portion of the global population, both physically and mentally. Current evidence suggests that the rapidly evolving coronavirus subvariants risk rendering vaccines and antibodies ineffective due to their potential to evade existing immunity, with enhanced transmission activity and higher reinfection rates that could lead to new outbreaks across the globe. The goal of viral management is to disrupt the viral life cycle as well as to relieve severe symptoms such as lung damage, cytokine storm, and organ failure. In the fight against viruses, the combination of viral genome sequencing, elucidation of the structure of viral proteins, and identifying proteins that are highly conserved across multiple coronaviruses has revealed many potential molecular targets. In addition, the time‐ and cost‐effective repurposing of preexisting antiviral drugs or approved/clinical drugs for these targets offers considerable clinical advantages for COVID‐19 patients. This review provides a comprehensive overview of various identified pathogenic targets and pathways as well as corresponding repurposed approved/clinical drugs and their potential against COVID‐19. These findings provide new insight into the discovery of novel therapeutic strategies that could be applied to the control of disease symptoms emanating from evolving SARS‐CoV‐2 variants.https://doi.org/10.1002/mco2.254combination therapydrug resistancepathogenic targetsrepurposing therapiesSARS‐CoV‐2 |
| spellingShingle | Yiying Xue Husheng Mei Yisa Chen James D. Griffin Qingsong Liu Ellen Weisberg Jing Yang Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2 MedComm combination therapy drug resistance pathogenic targets repurposing therapies SARS‐CoV‐2 |
| title | Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2 |
| title_full | Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2 |
| title_fullStr | Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2 |
| title_full_unstemmed | Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2 |
| title_short | Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2 |
| title_sort | repurposing clinically available drugs and therapies for pathogenic targets to combat sars cov 2 |
| topic | combination therapy drug resistance pathogenic targets repurposing therapies SARS‐CoV‐2 |
| url | https://doi.org/10.1002/mco2.254 |
| work_keys_str_mv | AT yiyingxue repurposingclinicallyavailabledrugsandtherapiesforpathogenictargetstocombatsarscov2 AT hushengmei repurposingclinicallyavailabledrugsandtherapiesforpathogenictargetstocombatsarscov2 AT yisachen repurposingclinicallyavailabledrugsandtherapiesforpathogenictargetstocombatsarscov2 AT jamesdgriffin repurposingclinicallyavailabledrugsandtherapiesforpathogenictargetstocombatsarscov2 AT qingsongliu repurposingclinicallyavailabledrugsandtherapiesforpathogenictargetstocombatsarscov2 AT ellenweisberg repurposingclinicallyavailabledrugsandtherapiesforpathogenictargetstocombatsarscov2 AT jingyang repurposingclinicallyavailabledrugsandtherapiesforpathogenictargetstocombatsarscov2 |